Skip to main content

Table 1 Characteristics of patients with HCC who were stratified according to etiology of their liver disease

From: Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study

  NBNC HBV HCV P value
n = 514 n = 361 n = 1271 NBNC versus HBV NBNC versus HCV
Age (years) 72 (21–90) 58 (31–80) 68 (28–84) < 0.001 < 0.001
Sex (male/female) 417/97 294/67 841/430 NS < 0.001
Alcohol consumption 330 (64.2%) 207 (57.3%) 562 (44.2%) 0.024 < 0.001
Antibody to hepatitis B core antigen 179 (34.8%) 361 (100%) 397 (31.2%) < 0.001 < 0.001
Body mass index (kg/m2) 24.3 (14.3–41.2) 22.8 (14.4–31.7) 22.2 (14.8–33.6) < 0.001 < 0.001
Diabetes mellitus 286 (55.6%) 73 (20.2%) 373 (29.3%) < 0.001 < 0.001
Hypertension 277 (53.8%) 82 (22.7%) 527 (41.4%) < 0.001 < 0.001
Hyperlipidemia 247 (48.0%) 105 (29.0%) 295 (23.2%) < 0.001  < 0.001
ALT (IU/l) 47 (6–435) 55 (10–644) 51 (9–847) < 0.001 < 0.001
Platelet counts (× 104/μL, median) 17.8 (2.7–57.3) 15.6 (1.9–38.1) 11.7 (1.1–28.1) < 0.001 < 0.001
FIB-4 index 3.89 (0.25–28.31) 4.93 (0.35–34.69) 6.63 (0.69–39.61) < 0.001 < 0.001
ALBI grade 1/2/3 231/242/41 176/154/31 453/741/77 NS < 0.001
Child–Pugh grade A/B/C 382/105/27 267/71/23 919/304/48 NS NS
Antinuclear antibody 68 (13.2%) 46 (12.7%) 188 (14.9%) NS NS
Antimitochondrial antibodies 15 (2.9%) 3 (0.8%) 20 (1.6%) 0.032 NS
HCC stagea (I/II/III/IV) 54/188/141/131 61/103/90/107 332/467/321/142 0.006 < 0.001
  1. Continuous data are presented as medians and range, and categorical data are presented as numbers of patients
  2. aDetermined according to the criteria set by the Liver Cancer Study Group of Japan; HBV hepatitis B virus, HCV hepatitis C virus, NBNC negative for hepatitis B surface antigen and antibody to hepatitis C virus, ALT alanine aminotransferase, FIB-4 fibrosis-4, ALBI grade albumin-bilirubin grade, NS not significant